OPN Deficiency Increases the Severity of Osteoarthritis Associated with Aberrant Chondrocyte Senescence and Apoptosis and Upregulates the Expression of Osteoarthritis-Associated Genes
Authors:
Open Access
- 22 October 2020
- journal article
- research article
- Published by Wiley in Pain Research and Management
- Vol. 2020, 1-9
Abstract
Objectives. A recent work has reported that the elevated osteopontin (OPN) levels in the articular cartilage and synovial fluid are correlated with the progressive osteoarthritis (OA) joint damage, and OPN has a protective effect against OA by suppressing the expressions of OA-associated genes. The present study examined whether the OPN deficiency was susceptible to OA through the regulation of chondrocyte senescence and apoptosis and the expressions of OA-associated genes. Methods. The mRNA levels of COL2A1 and OPN were compared between human OA chondrocytes and normal chondrocytes. The effects of OPN siRNA on the SA-β-Gal expressions and the percentage of apoptotic chondrocytes were examined by using SA-β-Gal staining and apoptosis assay, and the effects on the expressions of COL2A1 and OA-associated genes (COL10A1, IL-1β, TNF-ɑ, MMP-13, and ADAMTS5) were examined by western blot analysis and quantitative real-time RT-PCR. Furthermore, an in vivo OA model was established to examine the effects of OPN siRNA on the senescence and apoptosis of OA chondrocytes and the expressions of OA-associated genes. Results. The mRNA levels of COL2A1 and OPN were decreased in knee OA chondrocytes in comparison with those in normal chondrocytes. The OPN deficiency enhanced the senescence and apoptosis of OA chondrocytes and increased the expressions of COL10A1, IL-1β, TNF-ɑ, MMP-13, and ADAMTS5 but decreased the expression of COL2A1. Meanwhile, OPN deficiency could result in severe, accelerated OA in vivo, which was also associated with enhanced senescence and apoptosis of chondrocytes and elevated expressions of OA-associated genes. Conclusions. The findings of this study suggest that the OPN deficiency can result in accelerated OA, which is associated with enhanced senescence and apoptosis of OA chondrocytes and the upregulated expressions of OA-associated genes.Keywords
Funding Information
- National Natural Science Foundation of China (81672225, 2016JC2038, 45, 2015 L01)
- Research and Development (81672225, 2016JC2038, 45, 2015 L01)
- Xiangya Clinical Big Data System Construction Project of Central South University (81672225, 2016JC2038, 45, 2015 L01)
- Central South University (81672225, 2016JC2038, 45, 2015 L01)
This publication has 33 references indexed in Scilit:
- Correlation between senescence‐associated beta‐galactosidase expression in articular cartilage and disease severity of patients with knee osteoarthritisInternational Journal of Rheumatic Diseases, 2013
- Phosphorylation of osteopontin in osteoarthritis degenerative cartilage and its effect on matrix metalloprotease 13Rheumatology International, 2012
- Cilostazol induces cellular senescence and confers resistance to etoposide-induced apoptosis in articular chondrocytesInternational Journal of Molecular Medicine, 2012
- Osteopontin Deficiency Suppresses Tumor Necrosis Factor-α–Induced Apoptosis in ChondrocytesCARTILAGE, 2012
- Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patientsOsteoarthritis and Cartilage, 2010
- Accelerated development of aging‐associated and instability‐induced osteoarthritis in osteopontin‐deficient miceArthritis & Rheumatism, 2009
- Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritisClinical Biochemistry, 2009
- Synovial tissue inflammation in early and late osteoarthritisAnnals of the Rheumatic Diseases, 2005
- ERK-1/2 and p38 Kinase Oppositely Regulate Nitric Oxide-induced Apoptosis of Chondrocytes in Association with p53, Caspase-3, and Differentiation StatusJournal of Biological Chemistry, 2002
- Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targetsArthritis & Rheumatism, 2001